TAMPA, FL / ACCESS Newswire / July 29, 2025 / The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, ...

Cosmetic surgeons are reporting a growing number of patients with sagging skin and facial hollowing after losing weight with ...

"We are extremely encouraged by the interim results received to date aligned with our primary study endpoint," said Richard Christopher, CEO of Lexaria. "DehydraTECH is continuing to demonstrate ...

Novo Nordisk (NVO) stock falls as the company names a new CEO and cuts outlook citing pressure on obesity drug sales. Eli ...

In the STEP-1 extension study, rapid weight regain was seen with semaglutide discontinuation. Semaglutide is associated with a high prevalence of adverse events, and its long-term safety is unknown.

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.

Perhaps most reassuring about semaglutide’s cardiovascular benefits is their durability over time. The protection against major adverse cardiac events persisted throughout the study’s follow ...

King's College London. "Semaglutide treats liver disease in two thirds of patients." ScienceDaily. ScienceDaily, 4 May 2025. <www.sciencedaily.com / releases / 2025 / 04 / 250430182815.htm>.